
Mark Sullivan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8640653/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 2019, 16, 185-204.	27.6	223
2	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Science Translational Medicine, 2021, 13, eabd5524.	12.4	62
3	Dimethyl sulfoxide (DMSO) exposure to human peripheral blood mononuclear cells (PBMCs) abolish T cell responses only in high concentrations and following coincubation for more than two hours. Journal of Immunological Methods, 2010, 356, 70-78.	1.4	31
4	A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2® in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet. Gastroenterology, 2011, 140, S-437-S-438.	1.3	31
5	Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. Drug Delivery and Translational Research, 2016, 6, 572-578.	5.8	24
6	The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrology Dialysis Transplantation, 2004, 19, 386-390.	0.7	20
7	Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis. Journal of Hepatology, 2002, 36, 6-7.	3.7	17
8	Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years. PLoS Neglected Tropical Diseases, 2018, 12, e0006837.	3.0	17
9	Moving candidate vaccines into development from research: lessons from HIV. Immunology and Cell Biology, 2009, 87, 366-370.	2.3	7
10	Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV. Journal of Hepatology, 2002, 36, 138.	3.7	6
11	Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. Journal of Hepatology, 2002, 36, 138.	3.7	6
12	Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy. Journal of Hepatology, 2002, 36, 7.	3.7	3
13	Non-Immunogenicity of Overlapping Gag Peptides Pulsed on Autologous Cells after Vaccination of HIV Infected Individuals. PLoS ONE, 2013, 8, e74389.	2.5	2
14	Changes in alanine aminotransferase (ALT) and YMDD mutation profile associated with switching from lamivudine (LAM) to either adefovir dipivoxil (ADV) or combination LAM plus ADV in chronic hepatitis B (CHB) patients with LAM resistance. Gastroenterology, 2003, 124, A715.	1.3	1